Novartis Looks To New Models For Neglected Disease Research
This article was originally published in PharmAsia News
Executive Summary
SINGAPORE - Novartis Head of Corporate Research Paul Herrling is touting a new model for developing drugs for infectious diseases and is presenting his ideas April 3 to a U.S. Institute of Medicine Working Group, which is advising President Barack Obama on neglected diseases
You may also be interested in...
Novartis Head of Corporate Research And Chairman, Novartis Institute For Tropical Diseases, Paul Herrling On The Need For Government Funding For Neglected Diseases: An Interview With PharmAsia News
Paul Herrling, Head of Corporate Research at Novartis and Chairman of the Novartis Institute For Tropical Diseases, Singapore spends a week each month in Singapore and for the rest he fulfills his other global commitments. Herrling sat down with PharmAsia News in Singapore to discuss research initiatives for neglected diseases and controversies revolving around his proposal for a fund to research neglected diseases by multiple governments.
Novartis Head of Corporate Research And Chairman, Novartis Institute For Tropical Diseases, Paul Herrling On The Need For Government Funding For Neglected Diseases: An Interview With PharmAsia News
Paul Herrling, Head of Corporate Research at Novartis and Chairman of the Novartis Institute For Tropical Diseases, Singapore spends a week each month in Singapore and for the rest he fulfills his other global commitments. Herrling sat down with PharmAsia News in Singapore to discuss research initiatives for neglected diseases and controversies revolving around his proposal for a fund to research neglected diseases by multiple governments.
Big Pharma More Willing To Cooperate On Neglected Disease Research But Funding Models Still Unclear
HONG KONG - Debate over how best to fund research and development of neglected diseases may be reshaped by changing patterns of cooperation among Big Pharma and non-industry groups